Abbott Buys StarLIMS for $123M to Strengthen Diagnostic Presence, Expand into New Markets

The acquisition "offers Abbott entry into new market segments, such as forensics, microbiology, and public health, which are new and complementary to Abbott’s existing diagnostics businesses," an Abbott official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories